NPPA demands ₹52.75 Cr over Lanol pricing; Akums says marketer Hetero bears prime responsibility
The demand — ₹18.95 Cr overcharge, an equal penalty, ₹14.85 Cr interest — names Akums' subsidiary Pure & Cure as a manufacturer. The stock closed −2.3% in the next session.
MID-CAP by market cap ≈ ₹11,531 Cr
₹52.75 Cr
overcharge + penalty + interest
₹732.60 Oct 16 · −2.3% on the day
−12.7% adjusted high ₹838.80 (Sep 23)
₹100.98 Cr
consolidated
At 16:38 IST on October 15 — after the market close — Akums Drugs and Pharmaceuticals informed the exchange that Pure and Cure Healthcare, its wholly-owned subsidiary, has received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) dated October 13, 2026. The demand is for ₹52,74,68,193, i.e. ₹52.75 crore, and relates to the formulation Lanol 1000 mg injection (100 ml), which Pure & Cure manufactures for its client Hetero Healthcare. The notice was issued to three parties — Hetero Healthcare as marketer, and Pure & Cure and Abaris Healthcare as manufacturers. The stock closed −2.3% at ₹732.60 in the next session.
What NPPA is demanding, and from whom
NPPA issues ₹52.75 Cr demand notice over Lanol 1000 mg injection pricing
Pure & Cure Healthcare, Akums' wholly-owned subsidiary, received an NPPA demand notice dated October 13, 2026 (received October 15 at 11:05 AM IST) for ₹52,74,68,193 — i.e. ₹52.75 crore. Per the filing, the notice states that the client, Hetero Healthcare, fixed the MRP of Lanol 1000 mg injection (100 ml) in excess of the prescribed limits under The Drugs (Prices Control) Order, 2013; the annexure describes the violation as manufacturing/marketing the formulation without obtaining prior price approval from the Government of India as specified under Section 15 of the DPCO. The notice names three parties: Hetero Healthcare (marketer), Pure & Cure and Abaris Healthcare (manufacturers).
Read:The headline number is material at the quarterly scale — ₹52.75 Cr against ₹100.98 Cr of Q1 FY27 consolidated net profit — but the filing's central claim is that the economic burden may not be Akums': the company says the prime responsibility to respond lies with the marketer, and that its supply agreements place DPCO liability solely on the marketing entity.
BSE filing, Oct 15, 2026The demand has three components, and the filing itemises each. The overcharging amount covers batches manufactured over a nearly seven-year span — December 2017 to August 2024 — the penalty is set at 100% of that overcharged amount, and interest is computed up to October 30, 2026.
Crore figures converted from the rupee amounts in the filing. The notice states the total impact 'on the parties' and does not apportion the amount among the three.
The question that matters for Akums holders is who ultimately pays. The company's filing stakes out its position twice: the prime responsibility to respond to the notice lies with Hetero Healthcare, being the marketer of the product, and the contractual arrangements point the liability the same way.
…in the ordinary course of business, the Company and its subsidiaries execute supply agreements with the marketing entity(ies) containing a clause that marketing entity shall be solely held liable for violation of DPCO provisions; and any penalty, fine, interest and other amount, as may be specified by the regulatory or statutory authority, in the event of any discrepancy found in the maximum retail price of the supplied medicine.
— Akums — Reg 30 intimation, October 15, 2026
Two things are worth separating here. What the filing states: the notice names all three parties, the MRP was fixed by the client, and Akums' supply agreements carry a clause making the marketer solely liable. What it does not state: that NPPA has accepted this allocation, or how the ₹52.75 Cr would be apportioned if it has not. This suggests the practical exposure to Pure & Cure depends on how the response — which the filing says is primarily Hetero's to make — is resolved, and that remains open as of the disclosure.
Material to a quarter, small against the market value
Sizing the number from the pack's own figures: ₹52.75 crore is roughly 0.5% of the ≈₹11,531 Cr market cap (15.74 Cr shares × ₹732.60 last close), and a little over half of one quarter's consolidated net profit — Q1 FY27 came in at ₹100.98 Cr, the strongest of the last five quarters. If the full amount crystallised on Pure & Cure, it would be a visible dent in a quarter's earnings; it would not be a balance-of-the-company event.
On the tape, the notice landed on a stock that was already correcting. From the October 7 close of ₹826.50 to October 15's ₹749.80, AKUMS fell −9.3% across six sessions before the filing reached the exchange — that slide predates the disclosure and cannot be attributed to it. The attributable move is October 16's −2.3% to ₹732.60, the first session after the 16:38 IST filing. The stock is now −12.7% off its 52-week adjusted high of ₹838.80 (September 23), and still well above its 52-week low of ₹409.30 (January 21).
₹838.80
adjusted · Sep 23, 2026
₹732.60 Oct 16, 2026
Oct 16, 2026
₹409.30
adjusted · Jan 21, 2026
The rest of the 60-day filing record is routine, which leaves the demand notice as the only material regulatory event in the window: analyst-meet intimations (one, the August 25 Antique Stock Broking event, was cancelled for medical reasons), a depository compliance certificate, an unsolicited ESG rating of 65 for FY2025-26 assigned by NSE Sustainability on publicly available information, and a trading-window closure from October 1 that runs until 48 hours after the Q2 FY27 results — whose board-meeting date, per that filing, is yet to be intimated. Promoter holding was unchanged at 75.26% between the March and June 2026 shareholding patterns.
The filings that would change the picture
The response
The filing says the prime responsibility to respond lies with Hetero Healthcare as marketer. Any further intimation on that response — or on how the ₹52.75 Cr is apportioned among the three parties — is the event that resolves whether Pure & Cure bears any of it.
The interest clock
The ₹14.85 Cr interest component is computed only up to October 30, 2026. If the matter runs past that date, watch whether subsequent disclosures restate the total.
Q2 FY27 results
The trading window closed October 1; the board-meeting date is to be intimated. Whether the results carry any provision or contingent-liability disclosure tied to the notice would show how the company itself is sizing the exposure.
The disclosure is precise about the facts and deliberate about the framing: a ₹52.75 crore demand exists, Akums' subsidiary is one of three named parties, and the company's stated position — backed by the supply-agreement clause it quotes — is that the marketer carries the liability. The data indicates the amount is material at the scale of one quarter's profit and small against the company's market value.
What the filing cannot yet say is how the authority and the three parties settle the allocation. Until a response or a follow-up disclosure lands, the question for holders — whether Akums or its marketing partner ultimately bears the ₹52.75 Cr — stays open, and the watch-list above is where the answer will first appear.
Informational and educational content only. Not investment advice.